Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

ialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel-T, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE or NEUVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE, NEUVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Reportlinker.com announces that a new market ... Portugal Pharmaceuticals and Healthcare Report Q3 ... Includes 3 FREE quarterly updates ... last quarter has led us to revise our ... previously, BMI expects Portugal,s ...
(Date:7/28/2014)... CLEVELAND , July 28, 2014  Surgical ... new members to its Business Advisory Board. New ... Senior Vice President for Business Development and New ... (Jim) Fulton , former Senior Vice President and ... unit. Surgical Theater applies flight simulation technology to ...
(Date:7/28/2014)... , July 28, 2014  Serco Inc., a ... the Company has been awarded a re-compete contract ... (NEMSCOM) and its Deployable Medical Systems.  Serco will ... personnel to provide world-class healthcare to meet warfighter ... across the globe. The five year contract has ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... , ATLANTA, Dec. 23 MiMedx Group, Inc. ... launched its first product, Paradis Vaso Shield(TM). In April ... for use as a cover for vessels following anterior vertebral ... hydrogel product protected by multiple patents and patent applications, as ...
... FRANCISCO, Dec. 23 Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing ... that management will present at the following upcoming investor conferences. , ... January 12, 2010, 9:40 a.m. PT, ... OneMedForum 2010, Wednesday, January 13, 2010, ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3
(Date:7/28/2014)... Bariatric Eating, a leading supplier of ... will be introducing three additional flavors to its Inspire ... additional flavors include: , Inspire Summer Melon - Natural ... Pomegranate Razz Berry -­ Pomegranate, razz and other berries ... , Bariatric Eating's Inspire protein powders use ...
(Date:7/28/2014)... Amy Norton HealthDay ... Tonsillectomies are commonly done to relieve sleep apnea in children, ... kids, weight gain -- especially if they,re already overweight. ... risk factor for a range of health problems -- including, ... kids who need it. Instead, they said, doctors and ...
(Date:7/28/2014)... dopamine-producing regions in the brain was able to arouse ... In the August issue of Anesthesiology , ... anesthetized with continuous doses of either agent would move, ... to electrical stimulation delivered to the ventral tegmental area ... the substantia nigra, did not induce the animals to ...
(Date:7/28/2014)... Southwestern Medical Center cancer researchers have found a ... activity of a mutated cancer gene common in ... (SML), interferes with the KRAS gene, or Kirsten ... proteins called K-Ras that influence when cells divide. ... dividing uncontrollably and turning cancerous. These mutations ...
(Date:7/28/2014)... July 28, 2014 Mirena IUD lawsuits ... device caused some users to suffer serious injuries after ... uterus continue to mount in U.S. courts, Bernstein Liebhard ... issued last month in New Jersey, at least 924 ... multicounty litigation underway in Bergen County Superior Court. Some ...
Breaking Medicine News(10 mins):Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena IUD Lawsuit Filings Exceed 920 in New Jersey Litigation, Bernstein Liebhard LLP Reports 4
... Colonic lipomas have been found in related literature. One ... 14 issue of the World Journal of Gastroenterology because ... discussed age and sex factors, clinical and histopathological findings, ... and previously available literature. , The article reported ...
... Food and Drug Administration (FDA) has awarded the ... $1 million Orphan Products Development grant to study ... skin or internal organs., The unique, interdisciplinary, and ... Drolet, M.D., professor of dermatology and pediatrics, at ...
... Researchers at the Board of Governors Gene Therapeutics Research ... first time that it is possible to sustain therapeutic ... to a year, even in the presence of an ... humans. , The researchers demonstrated in an animal ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... long-term outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... peptide (ANP) can lessen cardiac injuries after heart attack and ... a Japanese study in this week,s issue of The ... damaged heart muscle (infarct) and lessened what,s known as "reperfusion ...
... 26 AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Inc Webcast, When: November 1, 2007 @ 8:30 AM ... over the Internet -- Simply log on to the web at ... Contact: Lisa Gould of AMICAS, Inc, 617-779-7892. If you ...
Cached Medicine News:Health News:The largest colonic lipoma to date 2Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2
...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: